Laboratório de Biologia Molecular e Doenças Endêmicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Exp Parasitol. 2020 Mar;210:107849. doi: 10.1016/j.exppara.2020.107849. Epub 2020 Feb 3.
Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because long-term protection is typical in patients who recover from the disease. No human vaccine is yet approved for use, but several candidates are at various stages of testing. Live attenuated parasites, which stimulate long-term immune protection, have potential as effective vaccines, and their challenges relating to safety, formulation and delivery can be overcome. Here we review current data on the potential of live attenuated Leishmania vaccines and discuss possible routes to regulatory approval.
皮肤利什曼病是一个严重的公共卫生问题，主要影响到那些难以获得医疗保健的贫困人群。控制这种疾病主要依赖于那些低效、昂贵且难以提供的化疗方法。疫苗接种是一种有吸引力且可行的替代方法，因为从疾病中康复的患者通常会获得长期保护。目前还没有批准用于人类的疫苗，但有几种候选疫苗处于不同的测试阶段。减毒活寄生虫能够刺激长期免疫保护，具有作为有效疫苗的潜力，其与安全性、制剂和输送相关的挑战是可以克服的。本文综述了减毒活利什曼原虫疫苗的潜力的相关数据，并讨论了获得监管批准的可能途径。
